PL1637517T3 - Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego - Google Patents

Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego

Info

Publication number
PL1637517T3
PL1637517T3 PL04746867T PL04746867T PL1637517T3 PL 1637517 T3 PL1637517 T3 PL 1637517T3 PL 04746867 T PL04746867 T PL 04746867T PL 04746867 T PL04746867 T PL 04746867T PL 1637517 T3 PL1637517 T3 PL 1637517T3
Authority
PL
Poland
Prior art keywords
hydrogen atom
hexane
ester derivative
dicarboxylic ester
aminobicyclo
Prior art date
Application number
PL04746867T
Other languages
English (en)
Inventor
Akito Yasuhara
Kazunari Sakagami
Hiroshi Ohta
Atsuro Nakazato
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of PL1637517T3 publication Critical patent/PL1637517T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL04746867T 2003-06-26 2004-06-25 Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego PL1637517T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2003181930 2003-06-26
JP2003373511 2003-10-31
JP2004128663 2004-04-23
EP04746867A EP1637517B1 (en) 2003-06-26 2004-06-25 2-aminobicyclo 3.1.0 hexane-2,6-dicarboxylic ester derivative
PCT/JP2004/009398 WO2005000791A1 (ja) 2003-06-26 2004-06-25 2-アミノ-ビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸エステル誘導体

Publications (1)

Publication Number Publication Date
PL1637517T3 true PL1637517T3 (pl) 2011-04-29

Family

ID=33556154

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04746867T PL1637517T3 (pl) 2003-06-26 2004-06-25 Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego

Country Status (20)

Country Link
US (5) US7960579B2 (pl)
EP (3) EP2287147B1 (pl)
JP (1) JP4792971B2 (pl)
KR (1) KR101071507B1 (pl)
AT (1) ATE487690T1 (pl)
AU (2) AU2004252017B2 (pl)
BR (1) BRPI0411823A (pl)
CA (1) CA2530706C (pl)
CY (1) CY1110997T1 (pl)
DE (1) DE602004030007D1 (pl)
DK (2) DK1637517T3 (pl)
ES (1) ES2394175T3 (pl)
HR (1) HRP20100619T1 (pl)
MX (1) MXPA05013740A (pl)
NO (1) NO335004B1 (pl)
NZ (2) NZ580554A (pl)
PL (1) PL1637517T3 (pl)
PT (1) PT1637517E (pl)
SI (1) SI1637517T1 (pl)
WO (1) WO2005000791A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1637517T3 (pl) * 2003-06-26 2011-04-29 Taisho Pharmaceutical Co Ltd Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego
JP5776553B2 (ja) 2009-11-18 2015-09-09 大正製薬株式会社 酵素を用いた光学活性ビシクロ[3.1.0]ヘキサン誘導体の製造方法
US8642777B2 (en) 2009-11-19 2014-02-04 Taisho Pharmaceutical Co., Ltd Process for producing 3-alkoxy-2-amino-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative and intermediate thereof
KR101554793B1 (ko) * 2010-11-18 2015-09-21 일라이 릴리 앤드 캄파니 mGluR 2/3 길항제로서의 4-치환된-3-벤질옥시-비시클로[3.1.0]헥산 화합물
TWI520935B (zh) 2010-11-18 2016-02-11 美國禮來大藥廠 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物
WO2013062680A1 (en) * 2011-10-25 2013-05-02 Braincells, Inc. Novel compounds and compositions thereof for treating nervous system disorders
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
JP5983713B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸のプロドラッグを含有する医薬
FR3026843B1 (fr) * 2014-10-03 2016-11-18 Univ Pierre Et Marie Curie Paris 6 Procede de caracterisation du mecanisme de fissuration d'un materiau a partir de sa surface de rupture
CN109071418B (zh) 2016-04-18 2022-03-18 大正制药株式会社 氨基酸衍生物的前药
JP2020506895A (ja) 2017-01-17 2020-03-05 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System インドールアミン2,3−ジオキシゲナーゼおよび/またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物
KR101877672B1 (ko) 2017-04-03 2018-07-11 엘에스산전 주식회사 Ad컨버터
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US11501618B1 (en) * 2018-10-19 2022-11-15 Amazon Technologies, Inc. Security device with user-configurable motion detection settings
CN116444470B (zh) * 2023-03-29 2025-04-04 河南中烟工业有限责任公司 一种二羧酸二ddmp酯类化合物、制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
CN1247527C (zh) 1998-08-31 2006-03-29 大正制药株式会社 6-氟双环[3.1.0]己烷衍生物
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 6−フルオロビシクロ[3.1.0]ヘキサン誘導体
CH694053A5 (de) * 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
US6770676B2 (en) 2000-06-28 2004-08-03 Taisho Pharmaceutical Co., Ltd. Dicarboxylic acid derivatives
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
PT1459765E (pt) 2001-12-27 2008-10-03 Taisho Pharmaceutical Co Ltd Derivados de 6-fluorobiciclo [3.1.0] hexano
JP2007063129A (ja) * 2003-06-26 2007-03-15 Taisho Pharmaceut Co Ltd 2−アミノ−3−アルコキシビシクロ[3.1.0]ヘキサン誘導体
PL1637517T3 (pl) * 2003-06-26 2011-04-29 Taisho Pharmaceutical Co Ltd Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego
WO2005000790A1 (ja) 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. 2-アミノビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸誘導体

Also Published As

Publication number Publication date
ATE487690T1 (de) 2010-11-15
PT1637517E (pt) 2011-01-31
US8258133B2 (en) 2012-09-04
EP2123630B1 (en) 2012-07-25
US8076502B2 (en) 2011-12-13
KR101071507B1 (ko) 2011-10-10
KR20060024817A (ko) 2006-03-17
EP1637517B1 (en) 2010-11-10
NO20060428L (no) 2006-03-10
CA2530706C (en) 2012-11-27
AU2004252017B2 (en) 2009-10-08
HK1095318A1 (zh) 2007-05-04
US20100298561A1 (en) 2010-11-25
HRP20100619T1 (hr) 2011-01-31
US8350060B2 (en) 2013-01-08
US20120004232A1 (en) 2012-01-05
AU2009217374B2 (en) 2011-03-03
EP2123630A1 (en) 2009-11-25
CA2530706A1 (en) 2005-01-06
JPWO2005000791A1 (ja) 2006-10-19
AU2004252017A1 (en) 2005-01-06
BRPI0411823A (pt) 2006-08-08
DE602004030007D1 (en) 2010-12-23
EP1637517A4 (en) 2007-05-23
NZ544131A (en) 2009-11-27
JP4792971B2 (ja) 2011-10-12
EP1637517A1 (en) 2006-03-22
US20090306408A1 (en) 2009-12-10
EP2287147A3 (en) 2011-05-18
AU2009217374A1 (en) 2009-10-08
EP2287147A2 (en) 2011-02-23
ES2394175T3 (es) 2013-01-23
US8039647B2 (en) 2011-10-18
US20120028982A1 (en) 2012-02-02
US7960579B2 (en) 2011-06-14
SI1637517T1 (sl) 2011-01-31
EP2287147B1 (en) 2013-05-15
NO335004B1 (no) 2014-08-25
DK2123630T3 (da) 2012-10-22
CY1110997T1 (el) 2015-06-11
DK1637517T3 (da) 2011-01-31
MXPA05013740A (es) 2006-05-17
US20070021394A1 (en) 2007-01-25
WO2005000791A1 (ja) 2005-01-06
NZ580554A (en) 2011-01-28

Similar Documents

Publication Publication Date Title
SI1637517T1 (sl) Derivat estra 2-aminobiciklo 3.1.0 heksan-2,6-dikarboksilne kisline
MY139357A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
AU2002239463A1 (en) Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists
NZ515894A (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
AP1895A (en) Novel benzoimidazole derivatives useful as antiproliferative agents.
SG155938A1 (en) Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
BRPI0413876A (pt) tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
MX2008001152A (es) Benzimidazoles triciclicos y su uso como moduladores del receptor de glutamato metabotropico.
NO20045103L (no) Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
TW200510378A (en) N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
ATE171374T1 (de) Verwendung von 1-(aminoalkyl)-3-quinoxalin-2-on derivaten zur herstellung von neuroprotektiven mitteln
NZ515407A (en) 4-Phenyl-pyrimidine derivatives
TW200633984A (en) Amide compounds and activators of thrombopoietin receptor
WO2003057213A3 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
MXPA05006271A (es) Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
TW200637552A (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
DE60135016D1 (de) Indolderivate und deren verwendung in medikamenten
MX2009005676A (es) Dialquilamino alquil esteres de pivagabina como medicamentos para el tratamiento de alteraciones del sistema nervioso central.